



Cumulative Index

Volume 47

January	MINORITY ORAL HEALTH, pages 1-186
April	NUTRITION AND ORAL HEALTH, pages 187-430
July	INFECTIONS, INFECTIOUS DISEASES AND DENTISTRY, PART I, pages 431-604
October	INFECTIONS, INFECTIOUS DISEASES AND DENTISTRY, PART II, pages 605-774

Note: Page numbers of article titles are in **boldface** type.

A

- Abscess, mandibular, gram-positive
staphylococci in, 615
- Acquired immune deficiency syndrome. See
AIDS.
- Acyclovir, in herpes zoster, 523
- African American(s), children, prevalence
of *Streptococcus mutans* in, 89
in New York City, prevalence of
dental caries among, **57-65**
male, study of untreated syphilis in,
4-5
maternal transmission of
Streptococcus mutans in, **87-101**
preterm low birth weight and
periodontal disease among,
115-125
urban, incidence of orofacial injuries
in, 141
- Aging, functional factors of, affecting
nutritional status, 358
physiologic factors of, affecting
nutritional status, 356-357
psychosocial factors of, affecting
nutritional status, 357-358
- AIDS, 467
incidence of, 468
non-Hodgkin's lymphoma in,
541-542
periodontal disease and, 160
reporting of cases of, 467
US surveillance data on, 468
- Airborne transmission, of occupationally
acquired infections, 642
- Alcohol, as influence on nutritional status,
358-359
- American Dental Association, role of
dentistry in bioterrorism and, 733
statement on water used in dental
treatment, 553
- Amino acids, 195-196
- Anabolic steroids, 251
- Anorexia nervosa, diagnostic criteria for,
397
incidence of, 397
physical symptoms of, 398
systemic problems associated with,
390-391
- Anthrax, 736-738
cutaneous, 738
gastrointestinal, 737-738
- Antibiotic efflux pumps, multidrug, 631
- Antibiotic prophylaxis, as benefit to doctor,
675
financial aspects of, 674-675
for immunocompromised patients, 675
for patients at risk for oral metastatic
infections, 675
for reduction of bacteremias,
671-673
in immune deficiency, 727
nonvalvular cardiovascular devices
and, 675
principles of, 666-668
problems associated with,
665-679
surgical indications for, 666, 667
to prevent bacterial endocarditis, 665

- Antibiotic resistance, 623-639**
definition of, 632
dentistry and, 633-635
development of, 634-635
transposable, 628-629
- Antibiotics, beta-lactam, viridans group streptococci and, 626**
enzymatic inactivation of, 630
ideal duration of use of, 635
inappropriate use in dentistry, 633-634
macrolide, resistance to, 627
mechanisms of action of, 627-628
microbial resistance to, mechanisms of, 629-633
"new," 632
"recycling" of, 633
resistance of *Streptococcus viridans* to, 673
- Antifluoridationists, 228-229**
- Antiretroviral therapy, highly active, in HIV disease, 472-473, 477, 483**
oral side effects of, 473, 474
toxicities associated with, 473-474
- Antitubercular therapy, drug interactions in, 461**
- Arthritis, rheumatoid, and periodontitis, 584-585**
treatment of, 585
- Atherosclerosis, oral infections and, 575**
- B**
- B-cells, 642-643**
- Bacille Calmette-Guérin vaccine, 455**
- Bacillus anthracis, 733, 736-737**
- Bacteremia(s), incidence of, 668-669**
oral cavity and, 668-669
reduction of, antibiotic prophylaxis and, 671-673
viridans group streptococci, 626
- Bacteria, and systemic conditions with susceptibility to infection, 551**
as building blocks of biofilms, 546
cariogenic, xerostomia and, 320
cultures, sensitivity pattern of, antibiotic discs and, 617
gram-negative heterotrophic, in water, 546
in dental waterlines, 548-549
entry into patient during dental procedures, 550
potential pathogenicity of, 549
oral, and diet, 320
pneumonia and, 583-584
- Bacterial challenge, subgingival, host response to, among ethnic/racial group, 110-111**
- Bacterial cultures, from maxillofacial infections, media for culture of, 611**
processing of, problems associated with, 619
- Barrier techniques, to prevent transmission of tuberculosis, 460-461**
- Beta-lactamase enzyme, 630**
- Beta-lactamases, 630**
- Beverages, fluoride content of, 233**
- Binge eating disorder, 400**
- Biofilm(s). See also Bacteria.**
and dental equipment design, 547-548
definition of, 546
nature of, 546-547
quorum sensing and, 547
- Biological agents, 736-740**
CDC categories of, 736
- Biological warfare, history of, 734-735**
- Biomedical research, recruitment for, access to health care and, 7**
confidence in efficacy of treatments and, 8
difficulties in, 4
educational level and, 8
potential unpleasantness of, interventions and, 7
- Biopsies, for diagnosis of Creutzfeldt-Jakob disease, 507, 510-511**
- Bioterrorism, dentistry and, 733-744**
increasing threat of, 735
responding to, dentistry's role in, 741-743
- Bioweapons, 735**
- Bisphosphonates, 220**
- Blood, occupational exposures to, prevention of, 684-685**
occupational transmission of pathogens in, risk of, 682-684
- Blood count, complete, 268-271, 272**
- Blood dyscrasias, 719**
- Blood products, Creutzfeldt-Jakob disease and, 502**

- Blood tests, for diagnosis of
 Creutzfeldt-Jakob disease, 506
- Bloodborne infectious disease, healthcare workers with, American College Health Association and, 751
 American Dental Association and, 750
 Centers for Disease Control and Prevention and, 745-746, 747-748
 disability antidiscrimination laws and, 752-755
 employment discrimination cases against, 753-754
 legal issues for, **745-756**
 precautions for, 748
 risk for transmission, 745-746, 748-749
 Society for Healthcare Epidemiology of America, 750-751
 occupationally acquired, 642
- Body mass index/weight-for height ratio, for children, 280-281
- Bone, calcium in, 213-215
 effects of parathyroid hormone and calcitonin on, 215, 216
 formation and resorption of, 213-214
 health of, and periodontal disease, 215
- Bone density, total body, 219
- Bovine spongiform encephalopathy, 493, 495
- Bulimia nervosa, diagnostic criteria for, 399
 incidence of, 398-399
 medical consequences of, 399
- C**
- Caffeine, 251
 and ephedra, 251
- Calcitonin, 213, 214
 and parathyroid hormone, effects on bone, 215, 216
- Calcium, 247
 absorption of, 210-212
 and osteoporosis, 218-219
 dietary, and periodontal disease, 317
 domains in vertebrate body, 209
 duodenal cell and, 211-212
 excretion of, 217-219
 foods rich in, 210
 homeostasis, 212-213
 in bone, 213-215
 in luminal fluid, 210-211
 in mammals, 209
 in plasma, 212-213
 parathyroid hormone and, 213
 in teeth, 215-217
 nutrition and metabolism of, **209-224**
 sources of, 247
 transcellular movement of, 211
- Cancer, development of, dietary compounds and, 414
 incidence of, vegetable and fruit consumption and, 415
- Cancer patient, nutritional status of, 385-386
- Cancrum oris. See *Noma*.
- Candidiasis, oral pseudomembraneous, of buccal mucosa, 476
- Capsaicin, 252
- Carbohydrates, 191-193
 classifications of, 192, 324
 recommendations for diet, 192
 sugars, and sweeteners,
 caries-promoting potential of, 322, 323
- Cardiovascular disease, and periodontitis, 575-577
 epidemiologic studies in, 576, 578-579, 580, 581
 treatment of, 577
 atherosclerosis in, 575
 pathogenesis of, 576-577
 risk factors for, 575-576
- Caries. See *Dental caries*.
 dental. See *Dental caries*.
- Cell mediated deficiencies, 713
- Cellular immunity, impaired, pathogens associated with, 711
- Central nervous system, transmissible spongiform encephalopathies and, 500, 502-503
- Charles Drew University of Medical Sciences, 127, 178
- Chemotherapy, in tuberculosis, 457
- Chickenpox, 522
- Child(ren), African American, prevalence of *Streptococcus mutans* in, 89
 caries in, dairy products and, 325-326
 disorders in, nutrition-related, 287
 emotional development of, and foods for, 285-286
 food choices of, 294-295
 environmental influences on, 286

- Child(ren) (*continued*)
 food environment and, 296-297
 HIV-infected, oral manifestations in,
 clinical implications of, **159-174**
 nutrient requirements of, 281-284
 obesity in, 289-291
 physical development of, and foods
 for, 284-285
 snacking and drinking by, 295-296
 weight and height assessments in,
 280-281
- Chlorhexidine, treatment using, effect on
 maternal transmission of *Streptococcus*
mutans, 96-97
- Chronic wasting disease, 495
- Cleft lip/cleft palate, closure of,
 postssurgical feeding and, 309-312
 dental disease in children with, 313
 etiology of, 305-306
 impact on nutritional health and
 oral-motor development,
 305-317
 infants with, breast feeding and,
 312-313
 nutritional requirements of,
 307-312
 oral-motor development in, 306-307
- Coenzyme Q10, 250
- Committee on Diet and Health, 187
- Committee on Dietary Allowances, 187
- Complement deficiencies, pathogens
 associated with, 711, 713, 714
- Condyloma acuminatum, human papilloma
 virus-associated, 477, 482
- Consumption. See *Tuberculosis*.
- Cranial nerve, impaired function of,
 nutritional status and, 268, 270
- Creatine, 251-252
- Creutzfeldt-Jakob disease, acquired,
 498-501
 Kuru, 498
 transmission of, 501-502
 vCJD, 499-501
 as transmissible spongiform
 encephalopathy, 493
 associated with dental treatment,
 503-504, 506, 507-508
 clusters of, 504
 diagnosis of, 505-509
 identification of patients with, 508
 in exposure to bovine spongiform
 encephalopathy, 499
 incidence of, 497

- inherited, 498
 clinical features of, 498
 maxillofacial surgery in, 511
 percutaneous exposure to fluids of
 patients with, 510
 persons at risk of developing, 509-510
 possible causes of, 497-498
 suspected cases of, management of,
 509
 symptoms of, 497
- Cyclosporin, 723
- Cystic fibrosis, susceptibility to infections
 and, 551
- Cytokines, in wound healing, 374-377
- Cytomegalovirus, 540-541
 as clinical marker for AIDS, 525
 infection with, diagnosis of, 525
 in immunosuppressed patients,
 524
 in neonates, 524
 treatment of, 526
 transmission of, 524
- Cytotoxic drugs, neutropenia and, 716

D

- Dairy products, childhood caries and,
 325-326
- Delta hepatitis, 660
- Dental caries, analysis of, in HIV-infected
 children, 161
 and composition of whole saliva in
 minority populations, **67-85**
 causes of, 159
 diet and, synergy between, 319-321
 early childhood, 287-288
 in eating disorders, 402-403
 nutrition and, **319-336**
 prevalence among African Americans
 in New York City, **57-65**
 study of, clinical implications of,
 63-64
 data analysis in, 60
 discussion of, 62
 methods of, 59-60
 results of, 60-62
 prevention of, dietary factors in,
 325-327
 fluoride in, 225, 227-228
 promotion of, dietary factors in,
 321-325
- Dental disease, in children with clefts, 313
- Dental equipment, design of, biofilms and,
 547-548

- Dental health, diet and, 269-261
of older adults, 360
- Dental office, waterborne infections and, 545
- Dental practitioners, practice points for, 255
- Dental prevention programs, in eating disorders, 405-407
- Dental schools, recruitment of minorities to, 35
- Dental treatment, complications from, in HIV disease, 483-486
risk of bacterial endocarditis due to, 670-671
- Dental waterlines. See *Waterlines, dental*.
- Dentin, hypersensitivity of, in eating disorders, 403
- Dentist(s), ethnicity of population and, 30
illness of, due to exposure to contaminated dental treatment water, 552-553
role in response to bioterrorism, 741-743
transmission of tuberculosis by, 460
visits to, by race/ethnicity, 33-36
- Dentoalveolar surgery, dietary considerations and, 382-384
- Dentures, diet suggestions in use of, 364-365, 366
effect on food choices and general health, 361-362
effect on taste, swallowing, and chewing, 360-361
- Diabetes mellitus, and periodontitis, 585-586
treatment of, 586
dental treatment in, 389-390
- Diet(s), and dental caries, synergy between, 319-321
and dental health, 269-261
and nutrition, evaluation of, 271-275
in pediatric dentistry, **279-303**
effects on periodontal health, 349-351
habits, and oral health, 294-297
of older adults, recommendations for, 362-366
oral bacteria and, 320
pediatric, guidelines for, 281-286
recommendations for, for caries prevention, 327-328
to combat obesity, 415-421
- Diet and health guidelines for Americans, 189, 190
- Dietary counseling, for prosthodontic patients, **355-371**
in pediatrics, 297-300
- Dietary education, and dietary screening, in dental practice, 328-332
- Dietary factors, in prevention of caries, 325-327
in promotion of caries, 321-325
- Dietary reference intakes, 187-189
- Dietary screening, and dietary education, in dental practice, 328-332
for older adults, 362
- Dietary supplement(s), certification of, 246
definition of, 245-246
medications and, 265
- Disinfection, methods of, 702-703
of patient care items, infections and, 699-700
- DNA oncogenic viruses, 535-541
- Dwarfism, psychosocial, 292
-
- E**
- Eating, disordered, 292-293
subconscious, 296
- Eating disorders, dental prevention programs in, 405-407
oral manifestations of, 400-405
recognition and management of, in dental office, **395-410**
systemic problems associated with, 390-391
- Echinacea, 252
- Electroencephalogram, for diagnosis of Creutzfeldt-Jakob disease, 506
- Encephalopathy(ies), bovine spongiform, 493, 495
scrapielike spongiform, 495
transmissible mink, 495
transmissible spongiform, agents, inactivation of, 508
and dentistry, 503-504
animal, 493, 495
Creutzfeldt-Jakob disease as, 493
description of, 493
infection control and dental treatment in, 505, 507-508, 509
infectious agents in, 494-495
orofacial manifestations of, 503
pathogenesis of, 501
prions and, **493-516**
treatment of, 503

- Endocarditis, bacterial, absolute risk rate for acquiring, 671, 672
 antibiotic prophylaxis to prevent, 665
 oral micro-organisms and, 669-670
 periodontal disease and, 669
 prevention of, best case scenario for, 673
 risk of, due to dental treatment, 670-671
 Streptococcus viridans and, 668, 669
 infective, and oral bacteria, 577-583
 bacteria causing, 582
 conditions predisposing to, 582
 dental treatment and, 583
 pathogenesis of, 582
 treatment of, 582
- Endotoxin, 551
 results of exposure to, 551-552
- Enteral feeding, for surgical patient, 386-388
- Environmental factors, and health behavior, 25, 26-28
- Enzyme-linked immunosorbent assay, 470
- Eosinophils, 642
- Epstein-Barr virus, neoplasms associated with, 538-539
 oral hairy leukoplakia and, 527
 transmission of, 539
- Epstein-Barr virus infection, chronic active, 526
 malignancies associated with, 526-527
 symptoms of, 526
- Ergogenic acids, 250-252
- Erythema multiforme, recurring, recurrent herpes simplex virus and, 520
- Ethambutol, in tuberculosis, 457
 side effects of, 462
- F**
- Failure to thrive, protein energy malnutrition and, 288-289
- Fat(s), daily requirements of, 194-195
 dietary, 193-194
 oral health and, 195
 polyunsaturated, 194
- Fat substitutes, 195
- Fluid hydration, for surgical patient, 388-389
- Fluoride(s), added to water, 225, 226-229
 daily ingestion of, 235-236
 dietary supplements, 229-230
 in caries prevention, 225, 227-228
 role in nutrition, **225-243**
 sources in diet, 232
 therapeutic, 226-232
 to treat osteoporosis, 220-221
 toxicity, 236-238
- Fluoroquinolones, resistance to, viridans group streptococci and, 627
- Fluorosis, skeletal and dental, 236-238
- Food(s), choices of, for children, 294-295
 fluoride content of, 232-233
 functional, 411-413
 examples of, 412
 rationale for, 412-413
 labels on, 190
- Food environment, children and, 296-297
- Food guide pyramid, 189, 191
- Food pyramid, for older adults, 363, 366
- Forsyth Institute laboratories, 179
- Fructose, malabsorption of, 291-292
- G**
- Garlic, 252-253
- Gingival disease, in HIV disease, 482, 483
- Gingivitis, 337-338
 acute necrotizing, incidence of, 560-561
 precursor to noma, 559-560, 564-565
 necrotizing ulcerative, fusobacteria and spirochetes in, 616
- Ginseng, 253
- Granulocytopenia, 719, 722
- Green tea, 253
- Growth, definition of, 202
 nutrients and, 202
- Growth and development, normal, 279-281
- Growth factors, in wound healing, 377-378
- Guarana, 253
- H**
- Hairy leukoplakia, 476, 477
 Epstein-Barr virus and, 527

- Head and neck, tuberculosis of, 453
- Health, and health behavior, models for studying, 24-26
determinants of, 22-24
promotion of, nutrition for, **411-423**
- Health behavior(s), and health, models for studying, 24-26
and health perceptions, understanding of, **21-39**
environmental factors and, 25, 26-28
predictors of, 25
- Health care facility, transmission of tuberculosis in, risk categories for, 460
- Health care issues, promotion of, minorities in communications professions and, 35-36
- Health care provider(s), and
patient-provider issues, 29
bloodborne infectious disease in. See *Bloodborne infectious disease, healthcare workers with.*
future vaccinations for, 660-661
immunizations and, **641-664**
contraindications, precautions, and adverse reactions to, 657-658
immunocompromised, vaccine considerations for, 658-660
immunoprophylaxis for, recommended, 647, 648
professions included as, 646
specific vaccines for, 649-657
- Health insurance, by race/ethnicity, 27-28
- Health perceptions, and health behaviors, understanding of, **21-39**
- Heavy metals, antibiotic resistant genes and, 632
- Hematopoietic cell transplant, 721
posttransplant complications of, 721-722
- Hepatitis, acute, hepatitis A as cause of, 436
causes of, 432
chronic, hepatitis B as cause of, 437
definition of, 431
human viral, advances in diagnosis and management of, **431-447**
chronic, 433-434
diagnosis of, 432-434
blood test for, 432-433
imaging techniques for, 432
liver function tests in, 433
HIV disease and, 475
pathogenesis of, 434-443
symptoms of, 431
systems affected by, 434
types of, 434
- Hepatitis A, 646, 647-648
- Hepatitis A vaccine, 656-657
- Hepatitis A virus, acute hepatitis due to, 436
Centers for Disease Control and Prevention recommendation on, 435
countries with endemicity for, 435
infection with, management of, 444
pre-exposure prophylaxis and, 435
transmission of, factors increasing risk of, 435
- Hepatitis A virus vaccines, vaccination schedules for, 435, 436
- Hepatitis B vaccine, 646, 654-656, 661
- Hepatitis B virus, as cause of chronic hepatitis, 437
carriers of, 437
exposure to, assessment and emergency management of, 687-688
management of, 691
postexposure prophylaxis and, 686-687, 688-689, 690, 692
reporting of, 686-687
hepatitis C virus, and HIV disease, risk, prevention, and management of, **681-696**
in hepatocellular carcinoma, 540
infection with, treatment of, 444
morbidity and mortality associated with, 645-646
occupational transmission of, risk of, 683
risk groups for, 437
transmission of, 436
- Hepatitis B virus infection, vaccination against, 686
- Hepatitis B virus vaccine, recommended doses of, 438
- Hepatitis C, vaccine for, development of, 660-661
- Hepatitis C virus, chronic, 439
exposure to, assessment and emergency management of, 687-688
management of, 691-693
postexposure prophylaxis and, 686-687, 688-689, 690
reporting of, 686-687
genotypes of, 440

- Hepatitis C virus (*continued*)
 hepatitis B virus, and HIV disease,
 risk, prevention, and
 management of, **681-696**
 incidence of, 439-440
 infection with, management of,
 444-445
 neoplasms associated with, 540
 occupational transmission of, risk of,
 683-684
 risk groups for, 438, 439
 transmission of, 438
- Hepatitis D virus, 441
 and hepatitis B virus infection, 441
 genotypes of, 441
- Hepatitis Delta virus, 660
- Hepatitis E virus, 441-442
 infection with, management of, 445
- Hepatitis F virus, 442
 infection with, management of, 445
- Hepatitis G virus, 442-443
 infection with, management of, 445
- Hepatocellular carcinoma, viruses in
 development of, 540
- Herbal medicines, and surgical patient,
 381-382, 383
- Herbal supplements, 252-254
- Herpes labialis, recurrent, 519-520
- Herpes simplex infections, diagnosis of,
 cytology smears for, 521
 immunomorphologic tests for,
 521
 serologic tests for, 522
 virologic tests for, 520-521
 primary, 518-519
 recurrent, 519-520
- Herpes simplex virus(es), 540-541
 types of, 518
- Herpes zoster, 522-524
 acyclovir in, 523
 and postherpetic neuralgia, 523-524
 in immunocompromised patients, 523
 symptoms of, 523
- Herpesvirus 6, human, 527
 in immunocompromised patients,
 527-528
 treatment of, 528
- Herpesvirus 7, human, 528-529
- Herpesvirus-6B, roseola and, 527
- Herpesvirus infections, update on, **517-532**
- Herpesvirus type 8, neoplasia associated
 with, 539-540
- Herpesviruses, characteristics of,
 517-518
- Hispanic population, in United States,
 41-43
 oral health promotion for,
 obstacles to, 43
- Hispanic subgroups, in New York City,
 dental health status and treatment
 needs of, **41-55**
 study of, discussion of, 51-53
 methods of, 43-44
 results of, 44-51
- HIV, in neoplasms, 541-542
- HIV-associated Kaposi's sarcoma, oral
 mucosal lesions of, 539
 prevalance of, 541
- HIV disease, **467-492**
 and tuberculosis, 454-455
 antiretroviral drug-resistant
 transmission of, 474
 clinical staging of, 471
 course of, and laboratory monitoring
 of, 471
 dental treatment considerations in,
 483-486
 dentists in diagnosis of, 470
 diagnosis of, 470
 exposure to, assessment and
 emergency management of,
 687-688
 management of, 688
 postexposure prophylaxis and,
 686-687, 688-689, 690
 reporting of, 686-687
 hepatitis B virus, and hepatitis C virus,
 risk, prevention, and
 management of, **681-696**
 hepatitis viral infections with, 475
 medical management of, 472-475
 occupational exposure to, 469
 occupational transmission of, risk of,
 682-683
 opportunistic disease and, prevention
 and treatment of, 474-475
 oral mucosal lesions in, and
 periodontal disease, 475-482
 oral opportunistic diseases and,
 478-481
 pathogenesis of, 469-470
 reporting of cases of, 467
 salivary gland dysfunction in,
 477-482
 suppression of HIV viremia and,
 472-475

- testing for, 470
transmission of, 469
 by dentists, 746
 hepatitis B virus immunization
 and, 747
 prevention of, 747
vaccine for, development of, 661
- HIV-infected children, oral manifestations
in, **159-174**
 discussion of, 168-172
 study of, caries prevalence and
 incidence of, 164-165
 demographics and, 160-161
 dental caries analysis and,
 161
 methods of, 160-163
 oral mucosal lesion analysis
 and, 162, 165-166
 periodontal disease analysis
 in, 162, 166-168
 statistical analysis and,
 162-163
- Hormone replacement therapy, 220
- Hospital, inner-city public, population
served by, 128
profile of, 128
- Host defense, disorders affecting, 710-712
- Human immunodeficiency virus. See *HIV disease*.
- Humoral deficiencies, 713
- Huntsville Study, 12
-
- I**
- IgA deficiency, 712-714
- IgG levels, *Porphyromonas gingivalis*, and
low birth weight, 120, 121
- Illness, human, in exposure to contaminated
dental treatment water, 552-553
- Immune defense, functional defects in, 720
- Immune deficiency(ies), acquired, 715-727
antibiotic prophylaxis in, 727
common, 712-714
primary, 712-715
causes of, 712
- Immune response, 710
- Immune senescence, 348
- Immune status, alterations in, persons at
risk for, 348
- Immune suppression, and considerations
for dental care, **709-731**
- Immune system, 710
and periodontal disease,
 341-342
dysfunction of, results of, 710
- Immune system, immunizations and,
641-645
- Immunity, infection, and nutritional status,
interaction of, 340-349
malnutrition and, 343
nutritional strategies to enhance,
 350-351
- Immunization(s), active, 644
and immune system, 641-645
for health care providers,
 contraindications, precautions,
 and adverse reactions to,
 657-658
health care providers and, **641-664**
indicated for oral health personnel,
 645-646
passive, 644
process of, 643
terms associated with, 644
- Immunocompetent states, immunologic
events in, 710
- Immunocompromised host, dental
considerations in, 726-727
host integrity and, 723-724
oral health care for, 723
risk of infection in, 724
- Immunocompromised patients, antibiotic
prophylaxis for, 675
definition of, 709
management of, dental clinician and,
 709
- Immunodeficiency disease, common
variable, 714
severe combined, 714
- Immunodeficiency(ies), acquired, 715
causes of, 716
combined, 713
- Immunoglobulin abnormalities, pathogens
associated with, 711
- Immunoprophylaxis, recommended, for
health care providers, 647, 648
- Immunosuppressive drugs, posttransplant,
722-723
- Infant, nutrition of, transition stage of,
284
with clefts, breast feeding and,
 312-313
nutritional requirements of,
 307-312

- Infant formulas, fluoride content of, 234-235
- Infection(s), aerosolized, protection against
 inhalation of, 461
 and cleaning, disinfection, and
 sterilization of patient care items,
 699-700
 biofilm-mediated, 547
 cell-mediated immunity and,
 718-719
 control of, **697-708**
 in health care settings, 704
 precautions in, 698-699
 program development for,
 701-705
 program evaluation in, 706-707
 rationale for, 697-698
 Web-based resources for, 706
 effect on nutritional status, 346-348
 exposure to, prevention of, 699
 immunity, and nutritional status,
 interaction of, 340-349
 maxillofacial, bacterial cultures from,
 media for culture of, 611
 mortality due to, 623-624
 nutrition, and periodontal disease,
 337-354
 occupationally acquired, from
 airborne and bloodborne
 transmission, 642
 opportunistic, in
 immunocompromised host, 725
 oral, 360
 and systemic diseases, **575-598**
 oral metastatic, antibiotic prophylaxis
 for patients at risk for, 675
 prevention of, nutritional strategies
 for, 350-351
 risk of, in immunocompromised host,
 724
 susceptibility to, in
 immunocompromised host,
 724-725
 transplant recipient and, 721
 waterborne, dental office and, 545
- Infectious disease, diagnosis of, laboratory
 methodologies for, 614-615
 diagnostic modalities for, **605-621**
- Influenza, 646
- Influenza vaccine, 653-654
- Insurance, health, by race/ethnicity, 27-28
- Integrins, 629
- Intraoral and extraoral examination, in
 nutrition evaluation, 267-268
- Iron deficiency, in children, 293-294
- Isoniazid, in tuberculosis, 457
 side effects of, 461, 462
-
- K**
- Kaposi's sarcoma, 528
 epidemiologic forms of, 539
 HIV-associated, oral mucosal lesions
 of, 539
 prevalence of, 541
 malignant tumors induced by, 529
 pathogenesis of, 540
 sexual transmission of, 529
- Kaposi's sarcoma-associated herpesvirus,
 neoplasia associated with, 539-540
- Kava, 254
- King/Drew Medical Center, 128
- Koch's postulates, 533
- Kostmann's syndrome, 717
- Kuru, 498
-
- L**
- Labels, food, 190
- Leukoplakia, hairy, 476, 477
 Epstein-Barr virus and, 527
- Lip, recurrent herpes simplex infection of,
 519-520
- Lipids, dietary, 193-195
- Long-term-care facilities, antibiotic
 resistant micro-organisms and,
 624-625
- Low birth weight, IgG levels, and
 Porphyromonas gingivalis, 120, 121
 in preterm infants, and periodontal
 disease among African
 Americans, studies of, 116-117
 discussion of, 121-123
 materials and methods
 in, 117-119
 results of, 119-121
 sample size and power
 in, 118
 statistical analyses in,
 118-119
 and periodontal diseases, among
 African Americans, **115-125**
 definition of, 115
 predictors of, 120, 121
 periodontitis, 586-590
- T-Lymphotropic I virus, human, neoplasia
 and, 541
- Lysine, 246-247

M

Ma Huang, 251

Magnetic resonance imaging, for diagnosis of Creutzfeldt-Jakob disease, 507

Malignant disorders, and myelodysplasia, 719-720

Malnutrition, and immunity, 343
chronic, noma and, 565
enamel hypoplasia associated with, 320

Mandible, abscess of, gram-positive staphylococci in, 615

Masks, to prevent transmission of tuberculosis, 461

Maxillofacial infections, bacterial cultures from, media for culture of, 611

Maxillofacial surgery, in Creutzfeldt-Jakob disease, 511

Measles, 645, 649
mumps, rubella vaccine, 649-651, 660
noma and, 564, 565

Medications, as influence on nutritional status, 358
dietary supplements and, 265
herbal, and surgical patient, 381-382, 383

Meharry Medical College's School of Dentistry, 177, 178

Meningococcal disease, 648

Mercury, dental amalgam, 632

Metabolic response, in response to surgery/injury, 374, 375

Micro-organisms, antibiotic resistant, long-term-care facilities and, 624-625
mechanisms for genetic variation, 628
oral, bacterial endocarditis and, 669-670

Microbial disease, diagnosis and treatment of, 606
etiologies of, 605

Microbial resistance, 624
in oral cavity, 625-627

Microbial specimens, collection and transport of, 606-610
collection of, before antibiotic chemotherapy, 607
blood cultures and, 607
smear of fluid material and, 608
swabs and containers for, 607
transport of, 606-610

commonly submitted, collection and transport of, 610, 612-613
diagnostic techniques and methods for, 610-618
Gram-stained patient abscess smears, 609
results and laboratory evaluation of, reporting of, 618-620
transport of, for laboratory analysis, 608-609

Microbiologic flora, oral, 338-340

Micronutrients, deficiencies of, and immune response, 343-346

Microorganisms, periodontal disease due to, 339

Milk, fluoridated, 231

Minerals, 203-204
dietary sources of, 200-201
requirements for, 200

Mink encephalopathy, transmissible, 495

Minority populations, composition of whole saliva and caries experience in, **67-85**
destructive periodontal diseases and, **103-114**
oral health of, regional research centers for, legacy of, **175-181**
research in. See *Research Centers, Regional, for Minority Oral Health*.
recruitment of, to dental schools, 35
underserved, orofacial injuries in, **127-139**

Monocytes, 642

Mother, transmission of *Streptococcus mutans* by, in African American population, **87-101**

Mucositis, oral, pathogens associated with, 711

Mumps, 645, 650-651

Myelodysplasia, malignant disorders and, 719-720

Mycobacterium tuberculosis, 449, 450

N

National Center for Bioethics, 11

National Health and Nutrition Examination Survey, 58

Needle devices, with engineered safety features, 685

- Neonates, infection with cytomegalovirus, 524
- Neoplasm(s), associated with Epstein-Barr virus, 538-539
associated with hepatitis C virus, 540
associated with herpesvirus type 8, 539-540
associated with Kaposi's sarcoma-associated herpesvirus, 539-540
epidemiology pattern of, 534
growth of, viruses and, **533-543**
HIV in, 541-542
human papillomaviruses and, 535-536
human T-lymphotrophic 1 virus and, 541
pathogenesis of, 534-535
viral etiology of, criteria for establishing, 533
viruses linked to, 534
- Neuralgia, postherpetic, herpes zoster and, 522-524
- Neurohumeral mediators, in response to surgery/injury, 374
- Neutropenia, causes of, 716-717
congenital causes of, 717
definition of, 716
immune-mediated, 717
pathogens associated with, 711
severe congenital, 717
treatment-related, 717
- Neutrophils, 642
- New York University College of Dentistry, 58-59, 179
- Noma, as forgotten disease, **559-573**
clinical presentation of, 561-563
description of, 559
diagnosis of, 562-563
etiology and pathogenesis of, 563-567
history of, 559-560
incidence of, 560
initial oral lesions and, 561
lesions of, microbiota of, 565-566
reconstructive surgery in, 568-569
risk factors for acquiring, 564-565
social and cultural aspects of society of source, 567
survivors of, disfigurements in, 563
treatment of, 567-569
trigger organisms of, 566
trismus associated with, 563, 567, 568
World Health Organization noma network and, 569-570
- Noma neonatorum, 561
- Non-Hodgkin's lymphoma, in AIDS, 541-542
- Northeastern Minority Oral Health Research Center, 180
- Nutrients, 191-202
antioxidant properties of, 205
in oral tissues growth, development, and health, 202-205
- Nutrition, and dental caries, **319-336**
and oral health, **187-207**
and wound healing, 378-380
definition of, 187
diet and, evaluation of, 271-275
in pediatric dentistry, **279-303**
for health promotion, **411-423**
for surgical patient, **373-393**
gerodontic, for prosthodontic patients, **355-371**
infection, and periodontal disease, **337-354**
of older adults, optimizing of, 362-366
plaque biofilm and, 339-340
role of fluorides in, **225-243**
- Nutrition Labeling and Education Act of 1990, 190
- Nutrition-risk questions, 277-278
- Nutrition-risk screens, 260-262
- Nutritional screening, 259
- Nutritional status, clinical and laboratory assessment of, **259-278**
effect of infection on, 346-348
evaluation of, in surgical patient, 380-381
immunity, and infection, interaction of, 340-349
laboratory tests to assess, 268-271
medical history and, 263-265
of older adults, 355-356
patient history and, 262-263
physical assessment of, 265-268
systemic diseases associated with, 263, 269
- Nutritional supplements, 246-250
definition of, 246
ergogenic acids, and herbals, **245-258**
uses and concerns for dental practitioner, 248-249
- Nutritional support, for surgical patient, 386-389

O

- Obesity, childhood, 289-291
 dental treatment in, 391-392
 diets to combat, 415-421
- Occupational exposure, to contaminated dental treatment water, 552
- Older adults, dental health of, 360
 nutritional status of, 355-356
 optimizing diet and nutrition in, 362-366
- Oral cavity, bacteremias and, 668-669
 microbial resistance in, 625-627
- Oral fluids, testing for antibodies, in diagnosis of HIV disease, 470
- Oral health, dietary habits and, 294-297
 minority, regional research centers for, legacy of, **175-181**
 nutrition and, **187-207**
 status of, determination of, conceptual framework for, 23-24
- Oral health care, for immunocompromised host, 723
- Oral health care setting, diseases with predilection for transmission in, 647
- Oral health service, utilization of, and oral health status, factors affecting, 30, 31-33
- Oral health status, utilization of oral health service and, factors affecting, 30, 31-33
- Oral infections, and systemic diseases, **575-598**
- Oral mucosal lesions, analysis of, in HIV-infected children, 162
 HIV-associated, and periodontal disease, 475-482
 of HIV-associated Kaposi's sarcoma, 539
 of tuberculosis, 453-454
- Orofacial injury(ies), in underserved minority populations, **127-139**
 and associated risk factors, 132-135
 and recurrent injury, 135-136
 discussion of, 136-137
 nature of injuries and, 131-132
 patient sociodemographics and, 130-131
 socioeconomic impacts of, 132
 spectrum of, 129
 studies of, background of, 128
 methods of, 129-130
 results of, 130-136

- substance use and, 133, 135
 incidence of, in urban African American population, 141
 psychosocial sequelae of, 145-152
 and correlates of, **141-157**
 study of, 142-156
 clinical implications
 observed in, 155-156
 patient characteristics in, 143
 patient compliance and, 153-154
 risk factors for injury and recurrent injury and, 143
 showing psychological distress, 144
 support needs during recovery and, 152-153
- University of California-LA/Drew Regional Research Center for Minority Oral Health Experience investigations, 142-156

Orthognathic surgery, dietary considerations and, 384-385

Osteoblasts, 214-215

Osteocytes, 215

Osteoporosis, calcium and, 219-221
 diet and, 293
 treatment of, 220-221

P

- Papillomaviruses, human, 535-538
 and neoplasia, 535-536
 lesions of, cells of, 537
 malignant potential of, 536
 replication of, 536
- Parathyroid hormone, and calcitonin, effects on bone, 215, 216
 calcium in plasma and, 213
- Parenteral nutrition, total, for surgical patient, 388
- Pathogens, waterborne, and dental waterlines, **545-557**
- Patient care items, and environmental surfaces, categories of, 700
 cleaning, disinfection, and sterilization of, infections and, 699-700
- Patient(s), illness of, due to exposure to contaminated dental treatment water, 552-553

- Patient(s) (*continued*)
transmission of tuberculosis to, 460
with tuberculosis, management of, 458-462
- Pediatric dentistry, diet and nutrition in, 279-303
- Pediatrics. See also *Child(ren)*.
dietary counseling in, 297-300
- Penicillin, 623
allergy to, 674
viridans group streptococci resistance to, 673
- Percutaneous injury, risk of, 684
postexposure prophylaxis in, 690
- Periodontal disease(s), AIDS and, 160
analysis of, in HIV-infected children, 162
and HIV-associated oral mucosal lesions, 475-482
bacterial endocarditis and, 669
bone health and, 215
causes of, 159
destructive, clinical and demographic parameters and, according to ethnic/racial group, 107, 108
in minority populations, 103-114
incidence and progression of, 104-109
risk indicators and risks associated with, 109-112
Surgeon General's report on, 103-104
dietary calcium and, 217
immune system and, 341-342
in eating disorders, 404
in HIV disease, 482, 483
microorganisms associated with, 339
nutrition, and infection, 337-354
preterm low birth weight and, among African Americans, 115-125
systemic diseases influencing, 575
vitamin C and, 247-250
- Periodontitis, 337-338
and diabetes mellitus, 585-586
treatment of, 586
cardiovascular disease and, 575-577
epidemiologic studies in, 576, 578-579, 580, 581
treatment of, 577
low birth weight and, 586-590
preterm birth and, 586-590
rheumatoid arthritis and, 584-585
treatment of, 585
- Periodontium, effects of dietary intake on, 349-351
- Phagocytic deficiencies, 713
- Phagocytic dysfunction, 718
- Pharyngitis, pharyngeal exudate in, 616
- Phytochemicals, compounds included in, 413
functions of, 413-414
health promoting effects of, 413
- Pica, 292
- Plant foods, as anticarcinogenic agents, 326-327
- Plaque biofilm, 338-339
host nutrition and, 339-340
- Plasma, calcium in, 212-213
parathyroid hormone and, 213
- Plasmids, 628-629
- Pneumocystis carinii pneumonia, HIV disease and, 474-475
- Pneumonia, and oral bacteria, 583-584
therapeutic consequences of, 584
community-acquired, 583
hospital-acquired, 583-584
- Porphyromonas gingivalis*, IgG levels, and low birth weight, 120, 121
- Posttraumatic stress disorder symptoms, following orofacial injuries, 146, 147, 148, 149, 150, 151
- Pregnancy, effect of, on maternal levels of *Streptococcus mutans*, 95
- Preterm birth, periodontitis and, 586-590
- Preterm infants, low birth weight, and periodontal diseases, among African Americans, 115-125
- Prion diseases. See *Encephalopathy(ies)*, transmissible spongiform.
- Prions, and human transmissible spongiform encephalopathies, 493-516
description of, 493, 505
in human trigeminal nerve and oral tissue, 504-505
locations of, detection of, animal studies of, 496
transmission by dental route, animal studies of, 496
- Prosthetic patients, gerodontology nutrition and dietary counseling for, 355-371
- Protein(s), complete, 196

dietary, 195-197
 inadequate intake of, 196
 serum circulating, nutritional status
 and, 381

Protein energy malnutrition, and failure to
 thrive, 288-289

Provitamin, 199-200

Psychosocial sequelae, of orofacial injuries,
 psychosocial sequelae of, and
 correlates of, 141-157

Pyrazinamide, in tuberculosis, 457
 side effects of, 462

Pyrogenic reactions, 551

R

Ramsay-Hunt syndrome, 523

Recommended dietary allowances, 187, 189

Regional Research Centers for Minority
 Oral Health. See *Research Centers,
 Regional, for Minority Oral Health.*

Research Centers, Regional, for Minority
 Oral Health, 21, 30, 31, 32, 58, 127,
 175, 181

meetings of, 176-177

Research centers, Regional, for minority
 oral health, goals of, 176
 legacy of, 175-181

Research issues, 254

Retroviruses, 541

Reye's syndrome, 522

Rheumatoid arthritis, and periodontitis,
 584-585
 treatment of, 585

Rifampin, in tuberculosis, 457
 side effects of, 461-462

RNA oncogenic viruses, 541

Roseola, human herpesvirus-6B and, 527

Rubella, 645, 651

Rumination, 292

S

Saliva, as complex secretion, 74-75
 function of, 320
 functions of, 67
 whole, caries prediction and, protocol
 for, 76
 cariogenic organisms in, 68

collection of, 68
 composition of, and caries
 experience, in minority
 populations, 67-85
 microbiological assay of, 68-69
 results of, 69-74
 statistical analyses of, 69
 pathogenic bacteria in, by
 ethnicity, 71, 72-73
 study(ies) of, discussion of, 74-82
 materials and methods for,
 68-69
 participants in, 68, 70
 smoking by participants in,
 and socioeconomic
 status, 68, 70

Salivary glands, dysfunction of, in HIV
 disease, 477-482
 hypertrophy of, in eating disorders,
 404

Salt, fluoridated, 230-231

Scrapie, 493, 495

Scrapielike spongiform encephalopathy, 495

Screening enzyme immunoassay, 470

Sepsis, 719

SMA panel, 271-273

Smallpox, 738-740
 course of disease, 739
 in United States, 738
 spread of, 739
 vaccination against, 739-740
 contraindications to, 740

Soft tissue, lesions of, in eating disorders,
 405

Spaulding classification scheme, of patient
 care items, 699-700

Splenectomy, pathogens associated with,
 711

Spongiform encephalopathies,
 transmissible. See
*Encephalopathy(ies), transmissible
 spongiform.*

Squamous cell carcinoma, human
 papillomavirus and, 536, 538

Stature, assessment of, in children, 280

Sterilization, methods of, 702-703
 of patient care items, infections and,
 699-700

Steroids, anabolic, 251

Stool, calcium excretion in, 218-219

- Streptococcus mutans*, epidemiology of,
88-92
findings from cross-sectional study,
89-90
findings from longitudinal studies,
90-92
maternal levels of, effect of pregnancy
on, 95
maternal transmission of, effect of
chlorhexidine treatment on,
96-97
effect of delivery on, 95-96
fidelity of, 93-95
in African American population,
87-101
maternal attributes to,
95-97
prevalence of, in African American
children, 89
in different ethnic populations,
88-89
transmission of, 92-93
- Streptococcus viridans*, antibiotic
resistance of, 673
bacterial endocarditis and, 668, 669
- Streptococcus pneumoniae*, mortality
due to, 625
- Streptomycin, in tuberculosis, 457
side effects of, 462
- Sugar(s), accusations against, 192-193
carbohydrates, and sweeteners,
caries-promoting potential of,
322, 323
forms of, in processed foods, 193
- Sugar substitutes, caries-promoting
potential of, 326
- Supplements. See also *Dietary
supplement(s)*; *Nutritional
supplements*.
interactions of, 254-255
questions regarding use of, 255
- Surgical patient, evaluation of nutritional
status in, 380-381
herbal medicines and, 381-382, 383
nutritional considerations in,
373-393
nutritional support for, 386-389
- Sweeteners, alternative, 193
carbohydrates, and sugars,
caries-promoting potential of,
322, 323
caries-promoting potential of, 326
- Syphilis, untreated, in African American
male, study of, 4-5
- Systemic diseases, associated with
nutritional status, 263, 269
oral infections and, 575-598
- Systemic inflammatory response syndrome,
719
-
- ## T
- T-cells, 643
- Taste and smell, as influence on nutritional
status, 359-360
- Tea tree oil, 253-254
- Teas, caries prevention and, 327
- Tetanus-diphtheria injections, 645
- Tetanus vaccine, 652-653
- Tetracycline, antibiotic resistant genes and,
632
- Tobacco use, carcinomas associated with,
537-538
- Tooth(Teeth), calcium in, 215-217
development of, nutrition and, 204
erosion of, in eating disorders,
400-402, 403
- Trace minerals, 200
- Transfusion-transmitted virus, 443
- Transmissible spongiform
encephalopathies. See
Encephalopathy(ies), *transmissible
spongiform*.
- Transplant recipient, cellular immunity and,
721
immune status of, 720
infections and, 721
medications taken by, 722
- Trauma surgery, dietary considerations and,
385
- Triglycerides, 194
- Trismus, associated with noma, 563, 567,
568
- Tuberculin, old, 455
- Tuberculin skin testing, 456
- Tuberculosis, 449-465, 647
as global, 449
extrapulmonary, manifestations of,
452
granulomatous inflammation in, 451
history of, 449
HIV disease and, 454-455, 475

incidence of, 449-450
 management of, 455-458
 management of dental patient with,
 458-462
 military, 453
 of head and neck, 453
 oral manifestations of, 453-454
 pulmonary manifestations of, 451
 reactivation of, 451-452
 secondary, 451
 testing for, 456
 transmission of, 450-453
 barrier techniques to prevent,
 460-461
 Centers for Disease Control and,
 458
 dental workers and, 459-460
 dentist-to-patient, 460
 in health care facility, risk
 categories for, 460
 treatment of, 456-458
 vaccination in, 455

Tuberculosis vaccine, 657

Tuskegee Legacy Project, 1-19, 180
 3 City study, 13-14
 4 City study, 14-15
 and additional pilot summer studies,
 12-13
 legacy of, 15
 origins of, 1-3
 proposed, significance of, 8-9
 questionnaire, development at
 workshop, 10-11
 summer pilot studies to develop,
 9-10
 unanticipated societal benefits of,
 11-12

Tuskegee syphilis study, background of, 3-8

U

Ubiquinone, 250

United States Food and Drug
 Administration (FDA), 705

University of California in Los Angeles, 127

University of California-LA/Drew Regional
 Research Center for Minority Oral
 Health Experience, investigations of
 orofacial injuries, 142-156

Urine, calcium excretion in, 217-218

V

Vaccination, against hepatitis B virus
 infection, 686

in tuberculosis, 455
 origin of term, 643

Vaccine(s), composition of, 644
 for immunocompromised health care
 providers, 658-660
 synthetic, 645
 tuberculosis, 657

Valerian, 254

Vancomycin-resistant enterococci, 624

Varicella, 522

Varicella vaccine, 645, 651-652

Varicella zoster virus, 522-524

Verrucous carcinoma, human
 papillomavirus and, 537-538

Viridans group streptococci, bacteremias,
 626
 beta-lactam antibiotics and, 626

Virus(es), and neoplastic growth,
 533-543

classification of, 533-534
 DNA oncogenic, 535-541
 RNA oncogenic, 541

Vitamin A, importance of, 205

Vitamin C, deficiency of, effects of, 205
 periodontal disease and,
 247-250

Vitamins, bioavailability of, 199
 classification of, 200, 201-202
 in foods, forms of, 199-200

Vomiting, chronic, oral symptoms of, 401

W

Water, as essential nutrient, 197

bottled, purity of, 199
 sources of, 199
 clean, treatments to produce,
 198-199
 daily requirements of, 197, 199
 dietary sources of, 197
 drinking, sources of, 198
 fluorination of, 226-227
 effectiveness in caries prevention,
 227-228
 opposition to, 228-229

Water bacteria, gram-negative
 heterotrophic, 546

Water systems, dental unit, contamination
 of, 548-553
 methods to control, 553
 sources of biofilm in, 548

Waterlines, dental, and health, 548-553
 biofilms in, 547-548
 diseases caused by, 550
 portals of entry of, 550
 design of, biofilms and, 547-548
 organisms in, potential
 pathogenicity of, 549
 waterborne pathogens and,
 545-557

Weight, assessment of, in children, 280

Weight-for-height ratio/body mass index,
 for children, 280-281

World Health Organization noma network,
 noma and, 569-570

Wound healing, 374-378
 nutrition and, 378-380

X

Xerostomia, cariogenic bacteria and, 320
 causes of, and dental problems caused
 by, 359
 due to chemotherapy, 386
 in eating disorders, 403

Y

Yohimbe, 253

